Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...